

## American College of Radiology ACR Appropriateness Criteria®

**Clinical Condition:** Liver Lesion Characterization

**Variant 1:** Typical benign on initial imaging, no history of malignancy.

Radiologic Procedure	Rating	Comments	<a href="#"><u>RRL*</u></a>
No imaging procedure at this time	8	If classic hemangioma, simple cyst or FNH, no further imaging needed. Recommend follow-up imaging at appropriate time.	None
US abdomen	5	Particularly useful if follow-up is to be performed.	None
Tc-99m sulfur colloid or Tc-99m RBC	4		Med
CT abdomen	4	Helical with late arterial and portal venous phase imaging.	Med
MRI abdomen with contrast	4		None
MRI abdomen without contrast	4		None
Arteriography liver	2		High
Percutaneous biopsy liver	2		NS
<b>Rating Scale:</b> 1=Least appropriate, 9=Most appropriate			<b>*Relative Radiation Level</b>

**Variant 2:** Typical benign on initial imaging, known history of extrahepatic malignancy.

Radiologic Procedure	Rating	Comments	<a href="#"><u>RRL*</u></a>
No imaging procedure at this time	8	If classic hemangioma, simple cyst or FNH, no further imaging needed. Recommend follow-up imaging at appropriate time.	None
US abdomen	5		None
CT abdomen	5	Helical with late arterial and portal venous phase imaging.	Med
MRI abdomen with contrast	5		None
MRI abdomen without contrast	4		None
Tc-99m sulfur colloid or Tc-99m RBC	2		Med
Arteriography liver	2		High
Percutaneous biopsy liver	2		NS
<b>Rating Scale:</b> 1=Least appropriate, 9=Most appropriate			<b>*Relative Radiation Level</b>

**Clinical Condition:****Liver Lesion Characterization****Variant 3:****Typical malignant hepatic mass on initial imaging.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b><a href="#">RRL*</a></b>
No imaging procedure at this time	7	Requires risk assessment and bio-chemical analysis for HCC. Recommend follow-up imaging at appropriate time.	None
Percutaneous biopsy liver	7	Requires risk assessment and bio-chemical analysis for HCC.	NS
CT abdomen	6	Helical with late arterial and portal venous phase imaging.	Med
MRI abdomen with contrast	6		None
US abdomen	4		None
MRI abdomen without contrast	4		None
Arteriography liver	2		High
Tc-99m sulfur colloid or Tc-99m RBC	2		Med
<b><u>Rating Scale:</u> 1=Least appropriate, 9=Most appropriate</b>			<b>*Relative Radiation Level</b>

**Variant 4:****Indeterminate on initial imaging, >1 cm, no suspicion or evidence of extrahepatic malignancy or liver disease.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b><a href="#">RRL*</a></b>
MRI abdomen with contrast	8	Either MRI or CT, depending on availability and institutional preference.	None
CT abdomen	8	Either MRI or CT, depending on availability and institutional preference. Helical with late arterial and portal venous phase imaging.	Med
US abdomen	5		None
MRI abdomen without contrast	5		None
Percutaneous biopsy liver	5	Requires risk assessment and bio-chemical analysis for HCC.	NS
Tc-99m sulfur colloid or Tc-99m RBC	3	May be of use if classic hemangioma or focal nodular hyperplasia lesion suspected.	Med
Arteriography liver	2		High
<b><u>Rating Scale:</u> 1=Least appropriate, 9=Most appropriate</b>			<b>*Relative Radiation Level</b>

**Clinical Condition:****Liver Lesion Characterization****Variant 5:****Indeterminate solitary mass on initial imaging, >1 cm, known history of extrahepatic malignancy.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b><u>RRL*</u></b>
Percutaneous biopsy liver	8		NS
CT abdomen	7	Helical with late arterial and portal venous phase imaging.	Med
FDG-PET whole body	7	Confirmation of metastatic disease if findings would influence patient management.	High
MRI abdomen with contrast	7		None
MRI abdomen without contrast	6		None
US abdomen	5		None
Tc-99m sulfur colloid or Tc-99m RBC	3		Med
Arteriography liver	2		High
<b>Rating Scale:</b> 1=Least appropriate, 9=Most appropriate			<b>*Relative Radiation Level</b>

**Variant 6:****Indeterminate mass on initial imaging, >1 cm, known or suspected liver disease associated with a high risk of hepatocellular carcinoma (chronic hepatitis, cirrhosis, hemochromatosis, etc).**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b><u>RRL*</u></b>
MRI abdomen with contrast	8	Either MRI or CT, depending on availability and institutional preference.	None
CT abdomen	8	Either MRI or CT, depending on availability and institutional preference. Helical with late arterial and portal venous phase imaging.	Med
Percutaneous biopsy liver	6	Depends on results of AFP.	NS
MRI abdomen without contrast	5		None
US abdomen	3		None
Tc-99m sulfur colloid or Tc-99m RBC	2		Med
Arteriography liver	2		High
<b>Rating Scale:</b> 1=Least appropriate, 9=Most appropriate			<b>*Relative Radiation Level</b>

**Clinical Condition:****Liver Lesion Characterization****Variant 7:****Small lesion on initial imaging, <1 cm.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b><u>RRL*</u></b>
No imaging procedure at this time	8	Recommend follow-up imaging at appropriate time.	None
US abdomen	7		None
MRI abdomen with contrast	5		None
CT abdomen	5	Helical with late arterial and portal venous phase imaging.	Med
MRI abdomen without contrast	4		None
Percutaneous biopsy liver	2		NS
Tc-99m sulfur colloid or Tc-99m RBC	2		Med
Arteriography liver	2		High
<b><u>Rating Scale:</u> 1=Least appropriate, 9=Most appropriate</b>			<b>*Relative Radiation Level</b>

# LIVER LESION CHARACTERIZATION

Expert Panel on Gastrointestinal Imaging: W. Dennis Foley, MD<sup>1</sup>; Robert L. Bree, MD, MHSA<sup>2</sup>; Spencer B. Gay, MD<sup>3</sup>; Seth N. Glick, MD<sup>4</sup>; Jay P. Heiken, MD<sup>5</sup>; James E. Huprich, MD<sup>6</sup>; Marc S. Levine, MD<sup>7</sup>; Pablo R. Ros, MD, MPH<sup>8</sup>; Max Paul Rosen, MD, MPH<sup>9</sup>; William P. Shuman, MD<sup>10</sup>; Frederick L. Greene, MD<sup>11</sup>; Don C. Rockey, MD.<sup>12</sup>

## Summary of Literature Review

Due to the high prevalence of benign focal hepatic lesions in adults, liver lesion characterization is an important objective of diagnostic imaging. For example, “incidental” liver masses discovered in healthy adults as well as liver lesions detected during staging of a known malignancy often need to be characterized.

Common benign liver masses include cysts and hemangiomas, and common malignant tumors are metastases and hepatocellular carcinoma (HCC). Less common liver tumors include focal nodular hyperplasia (FNH), liver cell adenoma (LCA), fibrolamellar HCC, intrahepatic cholangiocarcinoma, biliary cystadenoma and cystadenocarcinoma, lymphoma, hemangioendothelioma, hepatoblastoma in children, and a variety of sarcomas. On occasion, nontumorous masses seen as focal fat sparing, abscess, or hematoma may mimic liver tumors. Patients with cirrhosis are a special group in whom certain benign (regenerating nodules), premalignant (dysplastic nodules), malignant (HCC), and nontumorous (confluent hepatic fibrosis) masses are more prevalent.

The various variants in this document assume that state-of-the-art imaging studies have already been performed and that no prior imaging studies are available for comparison. For ultrasonography, this includes high-resolution sonography with color flow evaluation; for computed tomography (CT), it includes mechanically injected, intravenous (IV) contrast media-enhanced, dynamic helical, or multidetector helical CT; and, for magnetic resonance imaging (MRI), it includes T1- and T2-weighted imaging plus multiphase dynamic scanning with gadolinium chelate enhancement.

<sup>1</sup>Principal Author, Froedtert Hospital East, Milwaukee, Wisconsin.

<sup>2</sup>Panel Chair, Radia Medical Imaging, Everett, Washington.

<sup>3</sup>University of Virginia Health Science Center, Charlottesville, Virginia.

<sup>4</sup>Presbyterian Medical Center, Philadelphia, Pennsylvania.

<sup>5</sup>Mallinckrodt Institute of Radiology, St. Louis, Missouri.

<sup>6</sup>Mayo Clinic, Rochester, Minnesota.

<sup>7</sup>Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.

<sup>8</sup>Brigham & Women's Hospital, Boston, Massachusetts.

<sup>9</sup>Beth Israel Hospital, Boston, Massachusetts.

<sup>10</sup>University of Washington, Seattle, Washington.

<sup>11</sup>Carolinas Medical Center, Charlotte, North Carolina, American College of Surgeons.

<sup>12</sup>University of Texas, Southwestern Medical Center, Dallas, Texas, American Gastroenterological Association.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply society endorsement of the final document.

Reprint requests to: Department of Quality & Safety, American College of Radiology, 1891 Preston White Drive, Reston, VA 20191-4397.

## **Variant Development**

“Liver lesion characterization” is undertaken for hepatic masses seen by ultrasound (US), CT, or MRI. For the variant analysis, one can consider the following clinical situations:

- *Typical Benign*: Incidental liver lesion whose US, CT, or MRI imaging appearance is highly suggestive of a benign mass (cyst, hemangioma, focal fat, or FNH). This may occur in a patient with or without a known history of malignancy.
- *Typical Malignant*: Incidental liver lesion whose US, CT, or MRI imaging appearance is highly suggestive of a malignant mass (HCC, cholangiocarcinoma, or metastases) in a patient who may or may not have a known malignancy.
- *Indeterminate*: Larger than 1 cm incidental liver lesion whose US, CT, or MRI imaging appearance is indeterminate. This may occur in a patient with a background of normal liver, chronic liver disease, or known extrahepatic primary malignancy.
- *Small*: Subcentimeter liver lesions whose US, CT, or MRI imaging appearance is indeterminate, regardless of clinical history.

## **Diagnostic Tests**

For characterization of a liver lesion discovered by US, CT, or MRI, the following diagnostic studies may be considered:

- Dynamic contrast-enhanced CT (helical, or multidetector helical);
- MRI (including contrast enhancement with gadolinium chelates, iron oxide, and mangafodipir);
- Sonography;
- CT/PET;
- Nuclear scintigraphy (Tc-99m sulfur colloid or Tc-99m RBC);
- Angiography;
- Percutaneous biopsy;
- Follow-up imaging using the same test as the original study at an appropriate time interval.

Research on US contrast agents performed outside the United States has demonstrated high accuracy in characterizing liver lesions [1-3]. These agents have not been approved for hepatic imaging in the United States.

When considering possible studies for liver lesion characterization, it is assumed that a logical sequence will be followed. For example, if MRI and biopsy are considered appropriate tests, it is assumed that the biopsy will be done only if the MRI is nondiagnostic. In this case, both studies should be considered to be “indicated.”

## Recommendations

*Typical Benign Mass: No History of Malignancy.* Liver masses with typical imaging features of simple cyst, hemangioma, or FNH in patients who are not known to have, or are not suspected of having, a malignancy may be classified as benign [4-7]. Focal fat or focal spared areas in fatty livers can generally be diagnosed when typical features are seen on sonography, noncontrast CT, and, most reliably, MRI using in-phase and out-of-phase scanning.

*Typical Benign Mass: Known History of Malignancy.* Liver masses with typical imaging features of simple cyst, hemangioma, or FNH in patients who are known to have a malignancy may be considered benign [4-7]. However, if there is any doubt that the mass is benign; follow-up imaging (using the same test with which the lesion was initially detected) should be performed to make sure there is no change in the lesion appearance. Alternatively, MRI could be performed to help enable a definitive diagnosis. Presence of focal fat can be ascertained with MRI using in-phase and out-of-phase scanning.

*Typical Malignant Mass:* Lesions with typical sonographic, CT, or MRI features of a malignant mass do not require additional imaging, but confirmation with serum tumor markers (HCC) or percutaneous biopsy may be appropriate.

*Indeterminate Mass: Normal Liver.* For indeterminate masses, additional imaging may be required for tissue characterization. In these patients, follow-up imaging is not a practical option due to the need to initiate appropriate treatment. If the initial indeterminate imaging test is sonography or CT, then MRI may be considered for liver lesion characterization [8,9]. MRI would be preferred in pediatric and young adult patients due to lack of ionizing radiation. Nuclear scintigraphy is an option in patients with suspected FNH (technetium-labeled sulphur colloid) or possible neuroendocrine liver metastasis (somatostatin receptor scintigraphy).

*Indeterminate Mass: Suspect Metastatic Disease.* For indeterminate masses, additional imaging may be required for tissue characterization. In these patients, follow-up imaging is not a practical option due to the need to initiate appropriate treatment. In suspect metastatic disease, dynamic multidetector helical CT and contrast-enhanced multiphase MRI (gadolinium enhanced) [10,11] may be considered. CT/PET imaging is strongly suggested if the suspect metastasis will likely be FDG avid (eg, melanoma, colon and esophageal cancer, breast cancer, sarcoma) and a diagnosis of liver metastasis will influence patient management [12]. Nuclear scintigraphy is an option in patients with possible neuroendocrine liver metastasis (somatostatin receptor scintigraphy) [13,14].

*Indeterminate Mass: Cirrhotic Liver.* Characterization of liver lesions in a cirrhotic liver may be performed with either contrast-enhanced MRI (gadolinium) or dynamic multidetector helical CT, but that characterization is imperfect [15-18]. Characterization is more definitive for lesions larger than 2 cm in diameter. Although MRI may

sometimes differentiate among regenerating nodules, dysplastic nodules, and HCC, MRI (like CT and US) is best used to follow up lesions to determine change in appearance. Percutaneous biopsy is often needed to make a final diagnosis [19].

Additional MRI contrast agents including mangafodipir and ferumoxide may be of value distinguishing benign and malignant primary hepatocellular tumor and detecting metastatic disease. However, experience with the use of these agents is mainly limited to Phase III clinical trials, and these agents are not widely available for clinical use [20-27].

For indeterminate liver lesions in all the categories considered above, a biopsy should be considered if the findings from the additional imaging tests are inconclusive.

*Subcentimeter Lesion:* These lesions are difficult to characterize. In patients with extrahepatic primary malignancy, these small lesions are best evaluated with follow-up imaging because most are benign [28].

## Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#) document.

Relative Radiation Level Designations	
Relative Radiation Level*	Effective Dose Estimate Range
None	0
Minimal	< 0.1 mSv
Low	0.1-1 mSv
Medium	1-10 mSv
High	10-100 mSv

\*The RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, the region of the body exposed to ionizing radiation, the imaging guidance that is used, etc). The RRLs for these examinations are designated as NS (not specified).

## Supporting Document(s)

- [ACR Appropriateness Criteria® Overview](#)
- Evidence table under review

## References

1. Albrecht T, Hohmann J, Oldenburg A, Skrok J, Wolf KJ. Detection and characterisation of liver metastases. *Eur Radiol* 2004; 14 Suppl 8:P25-33.
2. Bartolotta TV, Midiri M, Quaia E, et al. Liver haemangiomas undetermined at grey-scale ultrasound: contrast-enhancement patterns with SonoVue and pulse-inversion US. *Eur Radiol* 2005; 15(4):685-693.
3. von Herbay A, Vogt C, Willers R, Haussinger D. Real-time imaging with the sonographic contrast agent SonoVue: differentiation between benign and malignant hepatic lesions. *J Ultrasound Med* 2004; 23(12):1557-1568.
4. Ferlicot S, Kobeiter H, Tran Van Nhieu J, et al. MRI of atypical focal nodular hyperplasia of the liver: radiology-pathology correlation. *AJR* 2004; 182(5):1227-1231.
5. McFarland EG, Mayo-Smith WW, Saini S, Hahn PF, Goldberg MA, Lee MJ. Hepatic hemangiomas and malignant tumors: improved differentiation with heavily T2-weighted conventional spin-echo MR imaging. *Radiology* 1994; 193(1):43-47.
6. Quinn SF, Benjamin GG. Hepatic cavernous hemangiomas: simple diagnostic sign with dynamic bolus CT. *Radiology* 1992; 182(2):545-548.
7. Vilgrain V, Uzan F, Brancatelli G, Federle MP, Zappa M, Menu Y. Prevalence of hepatic hemangioma in patients with focal nodular hyperplasia: MR imaging analysis. *Radiology* 2003; 229(1):75-79.
8. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. *Radiology* 2005; 236(1):166-177.
9. Hawighorst H, Schoenberg SO, Knopp MV, Essig M, Miltner P, van Kaick G. Hepatic lesions: morphologic and functional characterization with multiphase breath-hold 3D gadolinium-enhanced MR angiography--initial results. *Radiology* 1999; 210(1):89-96.
10. Bhattacharjya S, Bhattacharjya T, Baber S, Tibballs JM, Watkinson AF, Davidson BR. Prospective study of contrast-enhanced computed tomography, computed tomography during arteriography, and magnetic resonance imaging for staging colorectal liver metastases for liver resection. *Br J Surg* 2004; 91(10):1361-1369.
11. Ward J, Robinson PJ, Guthrie JA, et al. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. *Radiology* 2005; 237(1):170-180.
12. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). *Ann Surg* 2004; 240(3):438-447; discussion 447-450.
13. Dromain C, de Baere T, Lumbroso J, et al. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. *J Clin Oncol* 2005; 23(1):70-78.
14. Granberg D, Sundin A, Janson ET, Oberg K, Skogseid B, Westlin JE. Octreoscan in patients with bronchial carcinoid tumours. *Clin Endocrinol (Oxf)* 2003; 59(6):793-799.
15. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. *Am J Gastroenterol* 2003; 98(3):679-690.
16. Dodd GD, 3rd, Baron RL, Oliver JH, 3rd, Federle MP. Spectrum of imaging findings of the liver in end-stage cirrhosis: Part II, focal abnormalities. *AJR* 1999; 173(5):1185-1192.
17. Mori K, Yoshioka H, Takahashi N, et al. Triple arterial phase dynamic MRI with sensitivity encoding for hypervascular hepatocellular carcinoma: comparison of the diagnostic accuracy among the early, middle, late, and whole triple arterial phase imaging. *AJR* 2005; 184(1):63-69.
18. Taouli B, Goh JS, Lu Y, et al. Growth rate of hepatocellular carcinoma: evaluation with serial computed tomography or magnetic resonance imaging. *J Comput Assist Tomogr* 2005; 29(4):425-429.
19. Caturelli E, Solmi L, Anti M, et al. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. *Gut* 2004; 53(9):1356-1362.
20. Bartolozzi C, Donati F, Cioni D, Crocetti L, Lencioni R. MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis. *Eur Radiol* 2000; 10(11):1697-1702.
21. Bartolozzi C, Donati F, Cioni D, et al. Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. *Eur Radiol* 2004; 14(1):14-20.
22. Helmlinger T, Semelka RC. New contrast agents for imaging the liver. *Magn Reson Imaging Clin N Am* 2001; 9(4):745-766, vi.
23. Hori M, Murakami T, Kim T, et al. Detection of hypervascular hepatocellular carcinoma: comparison of SPIO-enhanced MRI with dynamic helical CT. *J Comput Assist Tomogr* 2002; 26(5):701-710.
24. Kim SH, Choi D, Kim SH, et al. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. *AJR* 2005; 184(4):1069-1076.
25. Savellano DH, Kostler H, Baus S, et al. Assessment of sequential enhancement patterns of focal nodular hyperplasia and hepatocellular carcinoma on mangafodipir trisodium enhanced MR imaging. *Invest Radiol* 2004; 39(5):305-312.
26. Stoker J, Romijn MG, de Man RA, et al. Prospective comparative study of spiral computer tomography and magnetic resonance imaging for detection of hepatocellular carcinoma. *Gut* 2002; 51(1):105-107.
27. van Etten B, van der Sijp J, Kruyt R, Oudkerk M, van der Holt B, Wiggers T. Ferumoxide-enhanced magnetic resonance imaging techniques in pre-operative assessment for colorectal liver metastases. *Eur J Surg Oncol* 2002; 28(6):645-651.
28. Schwartz LH, Gandras EJ, Colangelo SM, Ercolani MC, Panicek DM. Prevalence and importance of small hepatic lesions found at CT in patients with cancer. *Radiology* 1999; 210(1):71-74.

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.